However, not all animals obtain sufficient B12 through diet alone
How AOD-9604 works (mechanism, in plain clinical terms) The simplest way to understand AOD-9604 is this: GLP-1s help many patients eat less and improve glycemic control
The STEP 1 trial [1] demonstrated that participants receiving 2.4mg weekly semaglutide achieved an average weight loss of 14.9% of their initial body weight over 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021)
The case for microdosing for metabolic health rests on what the markers do, not on a trial that followed metabolic-health users for years
McCallum RW, Snape W, Brody F, et al
A physicians prescription is required